Sarepta Therapeutics (SRPT) Long-Term Deferred Tax (2012 - 2013)
Sarepta Therapeutics (SRPT) recorded quarterly Long-Term Deferred Tax of $133.6 million in Q4 2013, up 17.09% quarter-over-quarter from $114.1 million in Q4 2012, and up 17.09% on a YoY basis from $114.1 million in Q4 2012.
Sarepta Therapeutics (SRPT) Long-Term Deferred Tax (2012 - 2013) Analysis & Trends
Sarepta Therapeutics' Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $133.6 million for Q4 2013.
- In Q4 2013, Long-Term Deferred Tax rose 17.09% year-over-year to $133.6 million; the TTM figure through Dec 2013 stood at $133.6 million (up 17.09% YoY), while the FY2013 annual figure was $133.6 million, up 17.09% from the prior year.
- Long-Term Deferred Tax was $133.6 million for Q4 2013 at Sarepta Therapeutics, up from $114.1 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $133.6 million in Q4 2013 to a low of $114.1 million in Q4 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Sarepta Therapeutics | 1.84 Bn | 1.16 Bn | 291.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | 133.60 Mn |
| Dec 31, 2012 | 114.10 Mn |